Siltuximab
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Siltuximab: From Multicentric Castleman Disease to TAFRO Syndrome
Note on candidate selection: This evidence pack contains 10 TxGNN-predicted indications for siltuximab, ranked by raw prediction score. The top-scored candidate (“extracutaneous mastocytoma,” 99.64%) has zero supporting trials or literature, and its own mechanistic rationale states there is “no evidence support” for an IL‑6 link. TAFRO syndrome (rank 10 by score, but the only candidate reaching decision stage S2) has by far the strongest evidence base — an RCT, a consensus guideline, and 20 publications, several of which are TAFRO-specific. This report focuses on TAFRO syndrome as the clinically meaningful candidate.
One-Sentence Summary
Siltuximab is a chimeric anti-IL-6 monoclonal antibody approved for idiopathic multicentric Castleman disease (iMCD), based on literature evidence within this pack. The TxGNN model’s evidence-supported prediction is that it may also be effective for TAFRO syndrome, a condition now recognized as a clinical subtype of iMCD, with 0 dedicated clinical trials but 20 publications — including 1 RCT and 1 consensus guideline — supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Idiopathic Multicentric Castleman Disease (iMCD) — per literature evidence (PMID 25601959, 24958337); not confirmed via a formal regulatory record in this dataset |
| Predicted New Indication | TAFRO syndrome |
| TxGNN Prediction Score | 98.79% (rank 11,178 among all drug-disease pairs) |
| Evidence Level | L3 |
| Market Status | Not marketed (0 authorizations on file) |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, no structured MOA record is available for siltuximab in the regulatory dataset (flagged as a High-severity data gap, DG002). However, literature evidence within this pack (PMID 24958337, PMID 26394632) confirms that siltuximab is a chimeric human-mouse IgG1κ monoclonal antibody that binds human interleukin-6 (IL-6) with high affinity and specificity, thereby blocking IL-6 receptor signaling and its downstream inflammatory cascade.
Siltuximab’s proven indication, iMCD, is a lymphoproliferative disorder driven by dysregulated IL-6 overproduction in lymph nodes. TAFRO syndrome — characterized by Thrombocytopenia, Anasarca, Fever, Reticulin fibrosis/Renal insufficiency, and Organomegaly — is now widely recognized in the literature (PMID 38927484, 38087716) as a distinct, severe clinical phenotype falling within the iMCD spectrum rather than a separate disease entity.
Because both conditions share the same core pathophysiology of IL-6 pathway dysregulation, the mechanistic rationale for repurposing is strong: an agent that neutralizes IL-6 in iMCD would be expected to act on the same driver in iMCD-TAFRO. This is further supported by case-level clinical use already reported in the literature (PMID 36652167, 32564425, 34720942), even though no dedicated prospective trial in TAFRO syndrome has yet been conducted.
Clinical Trial Evidence
Currently no related clinical trials registered for TAFRO syndrome specifically.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 25042199 | 2014 | RCT | Lancet Oncology | Randomized, double-blind, placebo-controlled trial establishing siltuximab efficacy and safety in HIV-negative multicentric Castleman’s disease |
| 30181172 | 2018 | Guideline | Blood | International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease |
| 41345785 | 2025 | Meta-analysis | Annals of Hematology | Indirect comparison (single-arm meta-analysis, GLMM) showing siltuximab monotherapy improves PFS vs. rituximab-based regimens in iMCD |
| 32088937 | 2021 | Clinical Study | Korean J Internal Medicine | Clinical, laboratory, and radiologic improvement observed with siltuximab treatment in iMCD |
| 36652167 | 2023 | Case Report | Journal of Nephrology | Siltuximab monotherapy used in a TAFRO syndrome patient with MPGN/TMA renal involvement |
| 34720942 | 2021 | Case Report | Case Reports in Oncology | TAFRO syndrome treated empirically with anti-IL-6 therapy amid diagnostic uncertainty for iMCD |
| 32564425 | 2020 | Case Report | European Journal of Haematology | Frontline siltuximab plus rituximab used in a TAFRO syndrome case |
| 38927484 | 2024 | Review | Biomedicines | Management guidance for TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, organomegaly) |
| 38029058 | 2023 | Review | Journal of Medical Cases | Stepwise treatment approach for TAFRO syndrome, most iMCD cases controlled with anti-IL-6 therapy |
| 38087716 | 2024 | Review | Blood Reviews | Update on iMCD diagnosis and treatment advances, including approval of anti-IL-6 antibody siltuximab |
Market Information
No formal authorization records are available in this dataset (0 total licenses; market status: not marketed). This should be independently verified against the relevant regulatory authority’s product database before further action.
Safety Considerations
Please refer to the SmPC for safety information. Key warnings, contraindications, and drug-drug interaction data are all marked as data gaps in this pack (DG001, severity: Blocking — this currently prevents progression to the S1 safety screening stage).
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: TAFRO syndrome is increasingly recognized as a clinical subtype of iMCD, sharing the same IL-6-driven pathology as siltuximab’s established indication. This is supported by a foundational RCT, an international consensus guideline, and multiple TAFRO-specific case reports — but no dedicated prospective trial exists yet for this specific indication, and no drug/product regulatory data are on file.
To proceed, the following is needed:
- TFDA/EMA product labeling data (warnings, contraindications) — this is currently a blocking gap preventing safety pre-screening (DG001)
- Confirmed mechanism-of-action documentation from DrugBank (DG002)
- Confirmation of current market authorization status (0 licenses currently on file)
- A prospective clinical study or larger case series specifically enrolling TAFRO syndrome patients, rather than relying on iMCD trial extrapolation and isolated case reports
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.